Developer docs
API playgroundTry for free, no card

Search company profiles

DiscGenics

Full company profile

uuid0000l6h

Namestring
DiscGenics
Legal namestring
DiscGenics, Inc.
Websiteurl
discgenics.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

DiscGenics is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Salt Lake City, Utah, developing regenerative cell therapies for degenerative diseases of the spine. Its sole clinical asset is IDCT (rebonuputemcel), an allogeneic, homologous, injectable (non-surgical) cell therapy that uses proprietary Discogenic Cells cultured from donated human intervertebral disc tissue and prepared under cGMP conditions as a cryopreserved, off-the-shelf product administered via percutaneous intradiscal injection. IDCT is intended to treat mild to moderate adult lumbar disc degeneration, a leading cause of chronic low back pain, as a biologically restorative alternative to spinal fusion or artificial disc replacement. DiscGenics has accumulated 24 issued patents covering the Discogenic Cell platform, secured FDA Fast Track (2019) and RMAT (2023) designations, and received FDA approval to proceed with Phase III clinical evaluation in July 2024.

The company is pre-commercial and generates no product revenue, with commercialization expected only after regulatory approval and BLA filing. The intended go-to-market motion is enterprise field sales targeting hospital and ambulatory surgery center procurement channels, with distribution to spine surgeons, orthopedic spine specialists, and neurosurgeons. The company has assembled a commercial-ready operational ecosystem through partnerships with CCRM and GE Healthcare (GMP manufacturing scale-up), MedCision (automated cell thawing), and Cryoport (cold-chain logistics). DiscGenics pursues a dual-jurisdiction regulatory and commercial strategy in the United States and Japan, with Japanese PMDA Clinical Trial Notification approved in December 2018.

DiscGenics has raised over $71M in cumulative venture funding across a 2011 early round, a $14M Series B (2017), and a $50M Series C (2020) led by Ci:z Investment LLP with participation from Mitsubishi UFJ Capital, Medical Incubator Japan, CareNet, and Eagle Fund. The company operates with 11-50 employees and has been recognized with a Goldman Sachs "100 Most Intriguing Entrepreneurs" honor (2021) and a peer-reviewed Best Paper Award from the International Journal of Spine Surgery (2025). Founder Flagg Flanagan has served as Chairman and CEO since inception, and the company is privately held with no parent or subsidiary relationships.

Short descriptiontext

DiscGenics is a clinical-stage biopharmaceutical company developing IDCT (rebonuputemcel), an allogeneic, injectable Discogenic Cell therapy for treating lumbar degenerative disc disease. The company targets spine surgeons and chronic low back pain patients in the US and Japan.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative cell therapy, degenerative disc disease, allogeneic cell therapy, spine biologics, intervertebral disc treatment
Industry2 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Cell Therapy / Spine Biologics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cell Therapy Product Sales
TypeOne Time License
Description

As a pre-commercial clinical-stage biopharmaceutical company, DiscGenics has no current revenue. Upon regulatory approval, the expected revenue model is the sale of a commercially manufactured cell therapy product, billed as a one-time therapeutic procedure (single injection per treated disc). Revenue will flow through hospital and outpatient spine surgery center procurement channels upon FDA approval and commercial launch.

discgenics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

DiscGenics is a clinical-stage biopharmaceutical company developing IDCT (rebonuputemcel), an allogeneic, injectable cell therapy that uses proprietary Discogenic Cells derived from donated adult human intervertebral disc tissue to treat mild to moderate adult lumbar degenerative disc disease. The product is administered as a single percutaneous intradiscal injection in an outpatient setting, manufactured under cGMP conditions and cryopreserved for off-the-shelf use as a regenerative, non-surgical alternative to spinal fusion or disc replacement.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

DiscGenics is a clinical-stage biopharmaceutical company developing regenerative cell-based therapies for degenerative spine diseases. The company's primary product is IDCT (rebonuputemcel), an allogeneic injectable disc cell therapy that utilizes proprietary Discogenic Cells. IDCT is the company's core therapeutic candidate designed to treat mild to moderate degenerative disc disease through a single intradiscal injection, offering a non-surgical, potentially regenerative solution. Discogenic Cells serve as the therapeutic engine derived from donated adult human intervertebral disc tissue, manufactured under cGMP conditions and cryopreserved for off-the-shelf administration.

Product and service1 record
1IDCT (rebonuputemcel)
CategoryRegenerative cell therapy / spine biologics
Description

An allogeneic, injectable (non-surgical) cell therapy utilizing proprietary Discogenic Cells to treat mild to moderate adult lumbar disc degeneration. Administered via percutaneous intradiscal injection in an outpatient setting as an off-the-shelf cryopreserved dose for adult patients with symptomatic degenerative disc disease, intended as a regenerative alternative to spinal fusion or artificial disc replacement.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

DiscGenics partnered with CCRM, a leading Canadian cell therapy and regenerative medicine CDMO, and GE Healthcare to support manufacturing scale-up of its Discogenic Cell therapy for late-stage clinical trials and anticipated commercial launch. CCRM provides GMP manufacturing process development, scale-up, and regulatory support services.

Strategic tierCoreTypeTechnology or Integration
Description

DiscGenics participates in MedCision's ThawSTAR Early Adopter Program, which provides automated, standardized thawing solutions for cryopreserved cell therapy products. MedCision's ThawSTAR system is designed to ensure consistent, safe thawing of cell therapies in clinical trial and commercial settings, replacing manual water-bath thawing methods.

Strategic tierCoreTypeTechnology or Integration
Description

Cryoport provides temperature-controlled logistics and cold chain management services critical for the distribution of DiscGenics' cryopreserved Discogenic Cell therapy product, ensuring chain-of-custody integrity from GMP manufacturing through clinical site delivery.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mesoblast develops allogeneic mesenchymal stem cell therapies for inflammatory and degenerative diseases. It is the most directly comparable peer in late-stage regenerative cell therapy commercialization, competing in similar musculoskeletal and inflammatory indications.

TypeDirect peer
Description

BioRestorative Therapies develops autologous and allogeneic stem cell therapies, with a disc-derived stem cell program (Disc2System/BRTX-100) targeting chronic lumbar disc disease—directly overlapping DiscGenics' IDCT indication and mechanism.

TypeDirect peer
Description

Medipost commercializes Cartistem, an allogeneic umbilical cord blood-derived mesenchymal stem cell therapy for cartilage regeneration. Comparable allogeneic cell therapy commercial-stage competitor, with parallel Korean/Japanese regulatory experience.

TypeBroad incumbent
Description

Vericel markets MACI (autologous cell therapy for cartilage repair) and other cell-based therapies. It is a US-listed commercial cell therapy company operating in adjacent musculoskeletal regenerative indications with similar bioprocessing and surgical-channel go-to-market.

5Cynata Therapeutics
TypeEmerging player
Description

Cynata is developing induced pluripotent stem cell-derived mesenchymal stem cell therapies for musculoskeletal and inflammatory conditions. Early-stage but addressing the same regenerative cell therapy opportunity.

TypeEmerging player
Description

Lineage develops allogeneic cell therapies using its proprietary cell expansion platform for orthopedic, neurological, and other indications. Comparable platform technology and clinical-stage positioning.

TypeEmerging player
Description

BrainStorm is a late-stage cell therapy company developing autologous MSC-NTF therapies. Compares on cell therapy development playbook, manufacturing complexity, and regulatory pathway navigation.

TypeBroad incumbent
Description

Globus Medical (acquired NuVasive) is a leading spine surgery device incumbent offering fusion, motion preservation, and orthobiologic products. They represent the surgical alternative that IDCT aims to displace.

TypeBroad incumbent
Description

Medtronic's Spine division offers BMP-infused bone grafts and other orthobiologics used in spinal fusion. As the dominant spine incumbent, Medtronic represents the entrenched competitive threat and potential strategic acquirer.

TypeBroad incumbent
Description

Stryker operates a major spine and orthopedics franchise including biologics. Comparable as a large incumbent with the resources to acquire or compete with cell therapy entrants in the spine market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DiscGenics

Regenerative Cell Therapy / Spine Biologicsdiscgenics.com

DiscGenics is a clinical-stage biopharmaceutical company developing IDCT (rebonuputemcel), an allogeneic, injectable Discogenic Cell therapy for treating lumbar degenerative disc disease. The company targets spine surgeons and chronic low back pain patients in the US and Japan.

What DiscGenics does

DiscGenics is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Salt Lake City, Utah, developing regenerative cell therapies for degenerative diseases of the spine. Its sole clinical asset is IDCT (rebonuputemcel), an allogeneic, homologous, injectable (non-surgical) cell therapy that uses proprietary Discogenic Cells cultured from donated human intervertebral disc tissue and prepared under cGMP conditions as a cryopreserved, off-the-shelf product administered via percutaneous intradiscal injection. IDCT is intended to treat mild to moderate adult lumbar disc degeneration, a leading cause of chronic low back pain, as a biologically restorative alternative to spinal fusion or artificial disc replacement. DiscGenics has accumulated 24 issued patents covering the Discogenic Cell platform, secured FDA Fast Track (2019) and RMAT (2023) designations, and received FDA approval to proceed with Phase III clinical evaluation in July 2024.

The company is pre-commercial and generates no product revenue, with commercialization expected only after regulatory approval and BLA filing. The intended go-to-market motion is enterprise field sales targeting hospital and ambulatory surgery center procurement channels, with distribution to spine surgeons, orthopedic spine specialists, and neurosurgeons. The company has assembled a commercial-ready operational ecosystem through partnerships with CCRM and GE Healthcare (GMP manufacturing scale-up), MedCision (automated cell thawing), and Cryoport (cold-chain logistics). DiscGenics pursues a dual-jurisdiction regulatory and commercial strategy in the United States and Japan, with Japanese PMDA Clinical Trial Notification approved in December 2018.

DiscGenics has raised over $71M in cumulative venture funding across a 2011 early round, a $14M Series B (2017), and a $50M Series C (2020) led by Ci:z Investment LLP with participation from Mitsubishi UFJ Capital, Medical Incubator Japan, CareNet, and Eagle Fund. The company operates with 11-50 employees and has been recognized with a Goldman Sachs "100 Most Intriguing Entrepreneurs" honor (2021) and a peer-reviewed Best Paper Award from the International Journal of Spine Surgery (2025). Founder Flagg Flanagan has served as Chairman and CEO since inception, and the company is privately held with no parent or subsidiary relationships.

DiscGenics firmographics

Firmographics
Name
DiscGenics
Legal name
DiscGenics, Inc.
Website
https://discgenics.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
DiscGenics is a clinical-stage biopharmaceutical company developing IDCT (rebonuputemcel), an allogeneic, injectable Discogenic Cell therapy for treating lumbar degenerative disc disease. The company targets spine surgeons and chronic low back pain patients in the US and Japan.
Ownership category
akta.pro rank

DiscGenics industry classification

Industry
Product category
Regenerative Cell Therapy / Spine Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative cell therapy
  • Degenerative disc disease
  • Allogeneic cell therapy
  • Spine biologics
  • Intervertebral disc treatment

Where DiscGenics is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

DiscGenics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain

Revenue model

  1. Cell Therapy Product Sales: As a pre-commercial clinical-stage biopharmaceutical company, DiscGenics has no current revenue. Upon regulatory approval, the expected revenue model is the sale of a commercially manufactured cell therapy product, billed as a one-time therapeutic procedure (single injection per treated disc). Revenue will flow through hospital and outpatient spine surgery center procurement channels upon FDA approval and commercial launch.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

DiscGenics product offering

Product offering

Core offering

DiscGenics is a clinical-stage biopharmaceutical company developing IDCT (rebonuputemcel), an allogeneic, injectable cell therapy that uses proprietary Discogenic Cells derived from donated adult human intervertebral disc tissue to treat mild to moderate adult lumbar degenerative disc disease. The product is administered as a single percutaneous intradiscal injection in an outpatient setting, manufactured under cGMP conditions and cryopreserved for off-the-shelf use as a regenerative, non-surgical alternative to spinal fusion or disc replacement.

Product overview

DiscGenics is a clinical-stage biopharmaceutical company developing regenerative cell-based therapies for degenerative spine diseases. The company's primary product is IDCT (rebonuputemcel), an allogeneic injectable disc cell therapy that utilizes proprietary Discogenic Cells. IDCT is the company's core therapeutic candidate designed to treat mild to moderate degenerative disc disease through a single intradiscal injection, offering a non-surgical, potentially regenerative solution. Discogenic Cells serve as the therapeutic engine derived from donated adult human intervertebral disc tissue, manufactured under cGMP conditions and cryopreserved for off-the-shelf administration.

Differentiator

Problem solved

Functional benefit

Products and services

  • IDCT (rebonuputemcel) An allogeneic, injectable (non-surgical) cell therapy utilizing proprietary Discogenic Cells to treat mild to moderate adult lumbar disc degeneration. Administered via percutaneous intradiscal injection in an outpatient setting as an off-the-shelf cryopreserved dose for adult patients with symptomatic degenerative disc disease, intended as a regenerative alternative to spinal fusion or artificial disc replacement.

Companies that use DiscGenics

Customer profile

Segments1 record

Ideal customer profiles1 record

DiscGenics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature1 record

DiscGenics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • CCRM and GE HealthcarecoreStrategic or Co-development PartnerDiscGenics partnered with CCRM, a leading Canadian cell therapy and regenerative medicine CDMO, and GE Healthcare to support manufacturing scale-up of its Discogenic Cell therapy for late-stage clinical trials and anticipated commercial launch. CCRM provides GMP manufacturing process development, scale-up, and regulatory support services.
  • MedCisioncoreTechnology or IntegrationDiscGenics participates in MedCision's ThawSTAR Early Adopter Program, which provides automated, standardized thawing solutions for cryopreserved cell therapy products. MedCision's ThawSTAR system is designed to ensure consistent, safe thawing of cell therapies in clinical trial and commercial settings, replacing manual water-bath thawing methods.
  • CryoportcoreTechnology or IntegrationCryoport provides temperature-controlled logistics and cold chain management services critical for the distribution of DiscGenics' cryopreserved Discogenic Cell therapy product, ensuring chain-of-custody integrity from GMP manufacturing through clinical site delivery.

Scale indicators2 records

Recent moves8 records

Expansion highlights5 records

DiscGenics competitors and assessment

Company assessment

Direct peers

  • Mesoblast: Mesoblast develops allogeneic mesenchymal stem cell therapies for inflammatory and degenerative diseases. It is the most directly comparable peer in late-stage regenerative cell therapy commercialization, competing in similar musculoskeletal and inflammatory indications.
  • BioRestorative Therapies: BioRestorative Therapies develops autologous and allogeneic stem cell therapies, with a disc-derived stem cell program (Disc2System/BRTX-100) targeting chronic lumbar disc disease—directly overlapping DiscGenics' IDCT indication and mechanism.
  • Medipost: Medipost commercializes Cartistem, an allogeneic umbilical cord blood-derived mesenchymal stem cell therapy for cartilage regeneration. Comparable allogeneic cell therapy commercial-stage competitor, with parallel Korean/Japanese regulatory experience.

Broad incumbents

  • Vericel: Vericel markets MACI (autologous cell therapy for cartilage repair) and other cell-based therapies. It is a US-listed commercial cell therapy company operating in adjacent musculoskeletal regenerative indications with similar bioprocessing and surgical-channel go-to-market.
  • NuVasive (now Globus Medical): Globus Medical (acquired NuVasive) is a leading spine surgery device incumbent offering fusion, motion preservation, and orthobiologic products. They represent the surgical alternative that IDCT aims to displace.
  • Medtronic: Medtronic's Spine division offers BMP-infused bone grafts and other orthobiologics used in spinal fusion. As the dominant spine incumbent, Medtronic represents the entrenched competitive threat and potential strategic acquirer.
  • Stryker: Stryker operates a major spine and orthopedics franchise including biologics. Comparable as a large incumbent with the resources to acquire or compete with cell therapy entrants in the spine market.

Emerging players

  • Cynata Therapeutics: Cynata is developing induced pluripotent stem cell-derived mesenchymal stem cell therapies for musculoskeletal and inflammatory conditions. Early-stage but addressing the same regenerative cell therapy opportunity.
  • Lineage Cell Therapeutics: Lineage develops allogeneic cell therapies using its proprietary cell expansion platform for orthopedic, neurological, and other indications. Comparable platform technology and clinical-stage positioning.
  • BrainStorm Cell Therapeutics: BrainStorm is a late-stage cell therapy company developing autologous MSC-NTF therapies. Compares on cell therapy development playbook, manufacturing complexity, and regulatory pathway navigation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

DiscGenics social profiles

Digital presence

DiscGenics compliance and trust

Trust signal

Compliance3 records

DiscGenics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DiscGenics leadership team

Management profile

Number of profiles

Profiles7 records

DiscGenics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DiscGenics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DiscGenics

What does DiscGenics do?

DiscGenics is a clinical-stage biopharmaceutical company developing IDCT (rebonuputemcel), an allogeneic, injectable cell therapy that uses proprietary Discogenic Cells derived from donated adult human intervertebral disc tissue to treat mild to moderate adult lumbar degenerative disc disease. The product is administered as a single percutaneous intradiscal injection in an outpatient setting, manufactured under cGMP conditions and cryopreserved for off-the-shelf use as a regenerative, non-surgical alternative to spinal fusion or disc replacement.

Is DiscGenics a public or private company?

DiscGenics is a private company. It is classified as venture growth investor backed and is currently operating.

When was DiscGenics founded?

DiscGenics was founded in 2007. It employs 11 to 50 people.

Where is DiscGenics based?

DiscGenics is headquartered in Salt Lake City, United States, in the North America region.

How does DiscGenics make money?

One revenue line is on record: cell Therapy Product Sales.

Who are DiscGenics's main competitors?

Direct peers on record are Mesoblast, BioRestorative Therapies and Medipost. Broad incumbents are Vericel, NuVasive (now Globus Medical), Medtronic and Stryker. Emerging players are Cynata Therapeutics, Lineage Cell Therapeutics and BrainStorm Cell Therapeutics.

Does DiscGenics have an API?

No public API is recorded for DiscGenics.

What industry is DiscGenics in?

DiscGenics's product category is Regenerative Cell Therapy / Spine Biologics. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CGTLiveDiscGenics’ Discogenic Progenitor Cell Therapy Rebonuputemcel Cleared for Phase 3 Program in Lumbar Degenerative Disc DiseaseDiscGenics received FDA clearance to proceed with its Phase 3 clinical program for rebonuputemcel, an allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease. The pivotal and confirmatory trials are scheduled to begin enrollment in the fourth quarter of this year, with results intended to support a future biologics license application. This approval follows positive outcomes from earlier Phase 1/2 trials demonstrating significant pain reduction and safety.AijournDegenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-DelveInsight published a market research report projecting the degenerative disc disease market to grow from USD 1.2 billion in 2025 at a ~19% CAGR, reaching substantial size by 2036, with the United States representing approximately 75% of the 7MM market. Multiple companies are actively advancing regenerative therapies including SB-01 (Spine Biopharma), IDCT (DiscGenics), rexlemestrocel-L (Mesoblast and Grünenthal), BRTX-100 (BioRestorative Therapies), and others through various clinical trial phases, shifting treatment from symptom-focused approaches toward disease-modifying therapies. Recent developments include Phase III trial launches, positive topline results, regulatory designation awards, and strategic partnerships aimed at accelerating commercialization of these pipeline candidates.PR NewswireDegenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-DelveInsight has published a market research report projecting the degenerative disc disease (DDD) treatment market to grow at approximately 19% CAGR, reaching an estimated USD 1.2 billion across the 7MM (United States, EU4, United Kingdom, and Japan) in 2025. The United States represents the largest market segment, accounting for approximately 75% of total market size in 2025, with nearly 28 million diagnosed prevalent cases across the 7MM. The report highlights a shift toward regenerative and disease-modifying therapies, including cell-based treatments such as SB-01 (Spine Biopharma), IDCT (DiscGenics), rexlemestrocel-L (Mesoblast and Grünenthal), BRTX-100 (BioRestorative Therapies), and AMG0103 (AnGes), which are advancing through clinical development for DDD treatment.openPR.comDegenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, HistogenDelveInsight released a market forecast report projecting the Degenerative Disc Disease market to grow from USD 1.2 billion in 2025 to nearly USD 7.2 billion by 2036, driven by advancements in regenerative therapies and increasing disease prevalence. The report highlights recent clinical developments and regulatory milestones for key industry players, including FDA approvals for Companion Spine's DIAM system and positive Phase III results for Mesoblast's rexlemestrocel-L.FinancialContent Business PageDiscGenics Appoints Healthcare Entrepreneur and Medtech Executive Chad Falciani to Board of DirectorsDiscGenics, a privately held biopharmaceutical company developing regenerative cell-based therapies for degenerative spine diseases, has appointed Chad Falciani to its Board of Directors. Falciani brings healthcare entrepreneurship and medtech commercialization expertise as Founder and Chairman of medical technology company Curiteva. The appointment is intended to support DiscGenics as it advances IDCT (rebonuputemcel), its investigational allogeneic disc cell therapy, through late-stage clinical development and prepares for future commercialization.ACCESS NewswireDiscGenics Appoints Healthcare Entrepreneur and Medtech Executive Chad Falciani to Board of DirectorsDiscGenics, Inc. announced the appointment of Chad Falciani to its Board of Directors to leverage his expertise in healthcare entrepreneurship and medtech commercialization. This strategic move supports DiscGenics as it advances its investigational regenerative spine therapy, IDCT, through late-stage clinical development and prepares for future commercialization.BarchartDegenerative Disc Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, YuhanDelveInsight released a 2026 pipeline report detailing clinical trial progress and therapeutic developments for Degenerative Disc Disease, highlighting activities from companies such as DiscGenics, BioRestorative Therapies, and Angitia Biopharmaceuticals. The report notes that DiscGenics received safety board approval to proceed with its Phase III IDCT trial, while BioRestorative Therapies completed patient enrollment in its Phase II BRTX-100 study following FDA endorsement of its Phase III design. Additionally, the article mentions recent regulatory milestones including FDA approval for Companion Spine's DIAM system and CE Mark approval for ReGelTec's HYDRAFIL System.openPR.comDegenerative Disc Disease Clinical Trial Analysis 2026: Recent FDA Clearances, Ongoing Clinical Studies, and Emerging Treatment Landscape by DelveInsight | Mesoblast, DiscGenics, Biosplice TherapeuticDelveInsight published its 2026 Degenerative Disc Disease pipeline report, documenting over 15 therapeutic candidates from more than 15 companies in active clinical development, covering therapies from early preclinical stages through approved products. Key recent milestones include ReGelTec Inc.'s publication of HYDRAFIL System efficacy data (January 2026) and CE Mark approval (May 2025), Companion Spine's FDA approval of its DIAM Spinal Stabilization System (December 2025), DiscGenics' peer-reviewed study recognition (April 2025), Discure Technologies' entry into the FDA's TAP program (March 2025), and Spine BioPharma completing enrollment for its SB-01 Phase 3 trial (September 2024).